Loading ...
Sorry, an error occurred while loading the content.

901News article

Expand Messages
  • Matt960@aol.com
    Sep 25, 1998
    • 0 Attachment
      For your information. --Matt--


      Breakthrough Therapies for Leukemia Are at Hand, Researchers Conclude

      - Less Toxic, Immune-Based Treatments Show Tremendous Promise -

      WASHINGTON, Sept. 25 /PRNewswire/ -- Scientists from around the globe
      gathered today to announce breakthrough studies that show the body's immune
      system can be manipulated to help patients fight cancer. Dubbed
      Immunotherapy, the scientists agree these treatments show the most promise in
      launching an effective attack against leukemia, lymphoma and myeloma since the
      introduction of chemotherapy 50 years ago.

      "We are on the verge of ushering in an entirely new approach to fighting
      leukemia and lymphoma," said Dwayne Howell, President of the Leukemia Society
      of America. "Within the next few years, the treatment for these patients will
      be greatly improved."

      Attending the first Symposium on Immunotherapy of Leukemia and Lymphoma, many
      authorities in hematology, oncology, molecular genetics and immunology will be
      briefed on the latest research findings on the application and effectiveness
      of immunotherapies, which use cells of the immune system to prompt a tumor-
      killing response. Traditional chemotherapy and radiation, while tremendously
      helpful in the fight against leukemia and lymphoma, are toxic and attack
      healthy as well as cancerous cells in the body. Immunotherapies are targeted
      -- more specific and less toxic for the patient -- and are able to
      differentiate between cancerous and most non-cancerous cells, leaving most
      normal cells unharmed.

      The findings to be presented at the symposium demonstrate that immunotherapy
      may be particularly effective against hematologic, or blood- related cancers:
      leukemia, lymphoma and myeloma. Today, these cancers strike over 100,000
      Americans each year and kill over 57,000.

      Immunotherapy may be most effective when combined with other conventional
      treatments, like chemotherapy and radiation, to increase survival rates by
      improving the success of treatment, prolonging a patient's remission or even
      putting relapsed patients back into remission.

      "Finding a cure for leukemia and lymphoma is the ultimate goal. As
      physicians, though, we also look for ways to contain the disease in the
      interim, allowing patients to lead long, normal lives. We're very hopeful
      that immunotherapy may be coupled with chemotherapy and radiation therapy to
      achieve this," Dr. Marshall Lichtman, the Leukemia Society's executive vice
      president for research, said.

      The Three Primary Categories of Immunotherapy

      Antibody-Based Immunotherapy

      Antibodies, which are proteins produced by white blood cells, can recognize
      antigens on cancer cells -- molecules on a cell that help the immune system
      decipher whether it is foreign or normal. Scientists have found that, like
      other foreign cells in the body, many cancer cells express antigens that could
      potentially serve as antibody targets. Antibody-based therapies currently
      being studied exploit the ability of antibodies themselves to destroy cancer
      cells, or use antibodies as vehicles -- like smart bombs -- to carry a toxic
      agent, a radioisotope or a drug directly to a tumor site. Researchers have had
      the most success with antibodies made by mouse cells, known as monoclonal
      antibodies -- which are engineered in a laboratory to recognize and attack a
      specific antigen on tumor cells.

      Last year, the FDA approved the use of Rituxan(R), a monoclonal antibody used
      to treat patients with relapsed non-Hodgkin's lymphoma. Currently, scientists
      are reporting promising results from various other clinical (human) trials
      using antibody-based therapy. One such study at the Fred Hutchinson Cancer
      Research Center (FHCRC) uses antibodies, armed with a radioactive isotope, to
      target leukemia cells that may reappear in a relapse after a bone marrow
      transplant in patients with acute myelogenous leukemia. Patients receive this
      targeted treatment in preparation for the bone marrow transplant, in addition
      to the high-dose chemotherapy or radiation normally used prior to
      transplantation. Another study at FHCRC has shown the effectiveness of using
      an antibody to carry a drug to leukemia cells, achieving remission without the
      toxicity usually observed with conventional chemotherapy. This targeted
      antibody approach allows the delivery of greater amounts of either radiation
      or drugs -- increasing the chance of a more lasting remission. Because the
      delivery is so targeted, it causes less damage than non-targeted therapies.

      Cellular Immune Therapy

      Based on the promising results seen in patients with renal cell cancer and
      melanoma, scientists are also concentrating their efforts on cellular immune
      therapy -- or adoptive immunotherapy -- to treat patients with leukemia or
      lymphoma before they receive bone marrow transplants, or afterwards, if the
      patient relapses. In the laboratory, scientists isolate and then stimulate
      the immune system's disease-fighting lymphocytes, primarily T lymphocytes, so
      that they can recognize and attack cancerous cells in the body.

      Cellular immune therapy is also leading to breakthroughs in the success of
      bone marrow transplants. For example, researchers know that T lymphocytes
      have the ability to attack cancer cells. Therefore, to prevent or offset
      potential cancer recurrence after an allogeneic (donor) bone marrow
      transplant, physicians can give the patient a subsequent infusion of donor T
      lymphocytes to suppress the tumor cells.

      Cellular therapy is also at the heart of studies aimed at improving the
      outcome of autologous bone marrow transplants, in which the patient's own stem
      cells are used. Scientists are studying ways to trick the body into thinking
      that it's own leukemia cells are foreign, and attack them. This triggered
      immune response can prevent the patient from relapsing, the rate of which is
      excessively high in autologous bone marrow recipients.

      Vaccine Immunotherapy

      Also being discussed at this Symposium is the development of vaccines to treat
      leukemia, lymphoma and myeloma. Unlike traditional vaccine therapy, this
      approach does not prevent the disease. Instead, it lessens the chance of its
      recurrence by stimulating immune response to the tumor.

      Currently, scientists at Stanford University and the University of Southampton
      in England are studying the effectiveness of cancer vaccines. These new
      technique use proteins or genes unique to the tumor to generate an immune
      response stronger than what might occur naturally. At this stage, these
      vaccines are being tested on patients with lymphoma. However, the same
      concept can apply to other blood cancers, including myeloma and myeloid
      leukemia.

      "It's important to understand that these early studies show the utility of a
      new, third approach to the treatment of leukemia and lymphoma, known as
      Immunotherapy. Our hope is that this approach will increase the cure rate and
      decrease the side effects of current therapy," Dr. Lichtman said.

      The two-day symposium is sponsored by The Leukemia Society of America, which
      dedicated $20 million a year to scientific research for leukemia, lymphoma,
      myeloma and Hodgkin's disease in 1998, and Berlex Pharmaceuticals. Held on
      September 26-27, the Symposium on Immunotherapy of Leukemia and Lymphoma will
      involve more than 200 scientists from the fields of hematology, oncology,
      molecular genetics and immunology.

      SOURCE Leukemia Society of America

      CO: Leukemia Society of America

      ST: District of Columbia

      IN: MTC

      SU: PDT

      09/25/98 08:11 EDT http://www.prnewswire.com

      To edit your profile, go to keyword <A HREF="aol://1722:NewsProfiles">
      NewsProfiles</A>.
      For all of today's news, go to keyword <A HREF="aol://1722:News">News</A>